Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML

Blood (2025) 146 (21): 2608–2611.

https://doi.org/10.1182/blood.2025029391

Published: 2025

Includes: Supplemental data

Journal Articles

A pilot study of low-dose sirolimus to increase hematopoietic function in patients with RUNX1 familial platelet disorder

Leticia Campoverde, Warren Fiskus, Jillian Mullin, Hiam Abdel-Salam, Danielle Hammond, Aishwarya Sahasrabudhe, Andrew Frelinger, Alan Cantor, Kapil Bhalla, Anupriya Agarwal, Courtney DiNardo

Blood (2025) 146 (Supplement 1): 1435.

https://doi.org/10.1182/blood-2025-1435

Published: 2025

Journal Articles

Preclinical efficacy of dual BET/HAT inhibitor–based combinations against post myeloproliferative neoplasm secondary AML cells

Warren Fiskus, Christopher Mill, Lucia Masarova, Naveen Pemmaraju, Prithviraj Bose, Arnav Gupta, Hanxi Hou, Taghi Manshouri, Jayastu Senapati, Sanam Loghavi, Andrew Dunbar, Claes Wahlestedt, Courtney DiNardo, Kapil Bhalla

Blood (2025) 146 (Supplement 1): 5053.

https://doi.org/10.1182/blood-2025-5053

Published: 2025

Journal Articles

EP31670, a dual-BET + p300 inhibitor, demonstrates pre-clinical efficacy, including in combination with JAK inhibition, in the hMPLW515L adoptive transfer model of myelofibrosis (MF)

Linda Fabris, Warren Fiskus, Kavi O'Connor, Zachary Zaroogian, Shishir Waghray, Gautam Borthakur, Prithviraj Bose, Naveen Pemmaraju, Lucia Masarova, Taghi Manshouri, Kapil Bhalla, Claes Wahlestedt, Ross Levine, Andrew Dunbar

Blood (2025) 146 (Supplement 1): 3759.

https://doi.org/10.1182/blood-2025-3759

Published: 2025

Journal Articles

Identifying novel 'druggable’ targets via Npm1A-turboid fusion and mass spectrometry to overcome genetic or adaptive resistance to menin inhibitors in mtNPM1 AML

Christopher Mill, Warren Fiskus, John Davis, Christine Birdwell, Hanxi Hou, Claes Wahlestedt, Jayastu Senapati, Koji Sasaki, Sanam Loghavi, Branko Cuglievan, Tapan Kadia, Naval Daver, Courtney DiNardo, Kapil Bhalla

Blood (2025) 146 (Supplement 1): 1500.

https://doi.org/10.1182/blood-2025-1500

Published: 2025

Journal Articles

Preclinical activity of investigational menin inhibitor DSP-5336 (Enzomenib)-based combinations against MLL1-rearranged (MLL-r) or mutant-NPM1 AML models

Warren Fiskus, Christopher Mill, Christine Birdwell, John Davis, Kaberi Das, Hanxi Hou, Surbhi Sharma, Steven Warner, Zhizhou Ye, Alicia Matthews, Kevin Philip, Tapan Kadia, Courtney DiNardo, Naval Daver, Kapil Bhalla

Blood (2025) 146 (Supplement 1): 1497.

https://doi.org/10.1182/blood-2025-1497

Published: 2025

Journal Articles

ASXL1 mutations are associated with adverse outcomes in european leukemianet (ELN) 2024 favorable risk patients with Acute Myeloid Leukemia (AML) treated with venetoclax (VEN) containing low-intensity therapy (LIT)

Blood (2025) 146 (Supplement 1): 3399.

https://doi.org/10.1182/blood-2025-3399

Published: 2025

Journal Articles

Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2 -mutated post-MPN AML

Blood (2025) 146 (3): 341–355.

https://doi.org/10.1182/blood.2024027117

Published: 2025

Includes: Supplemental data

Journal Articles

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia

Mehrnoosh Tashakori, Tapan Kadia, Sanam Loghavi, Naval Daver, Rashmi Kanagal-Shamanna, Sherry Pierce, Dawen Sui, Peng Wei, Farnoosh Khodakarami, Zhenya Tang, Mark Routbort, Carol A. Bivins, Elias J. Jabbour, L. Jeffrey Medeiros, Kapil Bhalla, Hagop M. Kantarjian, Farhad Ravandi, Joseph D. Khoury

Blood (2022) 140 (1): 58–72.

https://doi.org/10.1182/blood.2021013983

Published: 2022

Includes: Supplemental data

Journal Articles

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

Blood (2018) 132 (16): 1664–1674.

https://doi.org/10.1182/blood-2018-04-846626

Published: 2018

Includes: Supplemental data

Journal Articles

Auranofin Induces a Reversible In-Vivo Stress Response That Correlates With a Transient Clinical Effect In Patients With Chronic Lymphocytic Leukemia

Nakhle S Saba, MD, Mondana Ghias, Rekha Manepalli, Kevin Schorno, MBA, Scott Weir, PharmD, PhD, Christopher Austin, MD, Kami Maddocks, John C. Byrd, MD, Suman Kambhampati, MD, Kapil Bhalla, MD, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 3819.

https://doi.org/10.1182/blood.V122.21.3819.3819

Published: 2013

Journal Articles

The Gold Compound Auranofin Induces Oxidative Stress and Apoptosis in Primary CLL Cells Independent of Classic Prognostic Markers and the Protective Effect of the Tissue Microenvironment

Nakhle Saba, MD, Min Shen, PhD, Mondana Ghias, Mohammed Farooqui, DO, Christopher Austin, MD, Kevin Schorno, MBA, Scott Weir, PharmD, PhD, Kapil Bhalla, MD, Adrian Wiestner, MD, PhD

Blood (2012) 120 (21): 865.

https://doi.org/10.1182/blood.V120.21.865.865

Published: 2012

Journal Articles

Pre-Clinical Efficacy of Combined Therapy with LSD1 Antagonist SP-2509 and Pan-Histone Deacetylase Inhibitor Against AML Blast Progenitor Cells

Warren Fiskus, Ph.D., Sunil Sharma, M.D., Sunil Abhyankar, MD, Joseph McGuirk, DO, David J. Bearss, PhD, Kapil Bhalla, MD

Blood (2012) 120 (21): 868.

https://doi.org/10.1182/blood.V120.21.868.868

Published: 2012

Journal Articles

Pre-Clinical Efficacy of Combined Therapy with Novel β-Catenin Antagonist BC2059 and Histone Deacetylase Inhibitor Against Cultured and Primary AML Blast Progenitor Cells

Kapil Bhalla, MD, Warren Fiskus, Ph.D., Stephen K. Horrigan, PhD, Sunil Abhyankar, MD, Joseph McGuirk, DO, Sunil Sharma, MD

Blood (2012) 120 (21): 287.

https://doi.org/10.1182/blood.V120.21.287.287

Published: 2012

Journal Articles

Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists

Aditya Mandawat, Warren Fiskus, Kathleen M. Buckley, Kelly Robbins, Rekha Rao, Ramesh Balusu, Jean-Marc Navenot, Zi-Xuan Wang, Celalettin Ustun, Daniel G. Chong, Peter Atadja, Nobutaka Fujii, Stephen C. Peiper, Kapil Bhalla

Blood (2010) 116 (24): 5306–5315.

https://doi.org/10.1182/blood-2010-05-284414

Published: 2010

Journal Articles

Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate

Yumin Hu, Weiqin Lu, Gang Chen, Hui Zhang, Yu Jia, Yue Wei, Hui Yang, Wan Zhang, Warren Fiskus, Kapil Bhalla, Michael Keating, Peng Huang, Guillermo Garcia-Manero

Blood (2010) 116 (15): 2732–2741.

https://doi.org/10.1182/blood-2009-11-256354

Published: 2010

Includes: Supplemental data

Journal Articles

Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor–resistant acute myeloid leukemia cells

Warren Fiskus, Rekha Rao, Pravina Fernandez, Bryan Herger, Yonghua Yang, Jianguang Chen, Ravindra Kolhe, Aditya Mandawat, Yongchao Wang, Rajeshree Joshi, Kelly Eaton, Pearl Lee, Peter Atadja, Stephen Peiper, Kapil Bhalla

Blood (2008) 112 (7): 2896–2905.

https://doi.org/10.1182/blood-2007-10-116319

Published: 2008

Journal Articles

HDAC6 inhibition enhances 17-AAG–mediated abrogation of hsp90 chaperone function in human leukemia cells

Rekha Rao, Warren Fiskus, Yonghua Yang, Pearl Lee, Rajeshree Joshi, Pravina Fernandez, Aditya Mandawat, Peter Atadja, James E. Bradner, Kapil Bhalla

Blood (2008) 112 (5): 1886–1893.

https://doi.org/10.1182/blood-2008-03-143644

Published: 2008

Journal Articles

Pan-Histone Deacetylase (HDAC) Inhibitor LBH589 Depletes CXCR4 Levels and Signaling, Exerting Synergistic Anti-Leukemia Activity in Combination with CXCR4 Antagonists.

Aditya Mandawat, BS, Warren Fiskus, PhD, Andrea Jakubowski, Rekha Rao, PhD, Zixuan Wang, PhD, Pravina Fernandez, MS, Yongchao Wang, MS, Pearl Lee, BS, Anand Jillela, MD, Peter Atadja, PhD, Nobutaka Fujii, PhD, Stephen C. Peiper, MD, Kapil Bhalla, MD

Blood (2007) 110 (11): 537.

https://doi.org/10.1182/blood.V110.11.537.537

Published: 2007

Journal Articles

Connectivity Mapping of BCL6 Targeted Therapy Guides Rational Design of Potent and Specific Non-Chemotherapy Combinatorial Regimens in DLBCL.

Leandro Cerchietti, MD, Maria E. Figueroa, MD, David Meyers, PhD, Philip A. Cole, PhD, Kapil Bhalla, MD, Ari Melnick, MD

Blood (2007) 110 (11): 523.

https://doi.org/10.1182/blood.V110.11.523.523

Published: 2007

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML

A pilot study of low-dose sirolimus to increase hematopoietic function in patients with RUNX1 familial platelet disorder

Preclinical efficacy of dual BET/HAT inhibitor–based combinations against post myeloproliferative neoplasm secondary AML cells

EP31670, a dual-BET + p300 inhibitor, demonstrates pre-clinical efficacy, including in combination with JAK inhibition, in the hMPLW515L adoptive transfer model of myelofibrosis (MF)

Identifying novel 'druggable’ targets via Npm1A-turboid fusion and mass spectrometry to overcome genetic or adaptive resistance to menin inhibitors in mtNPM1 AML

Preclinical activity of investigational menin inhibitor DSP-5336 (Enzomenib)-based combinations against MLL1-rearranged (MLL-r) or mutant-NPM1 AML models

ASXL1 mutations are associated with adverse outcomes in european leukemianet (ELN) 2024 favorable risk patients with Acute Myeloid Leukemia (AML) treated with venetoclax (VEN) containing low-intensity therapy (LIT)

Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2 -mutated post-MPN AML

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

Auranofin Induces a Reversible In-Vivo Stress Response That Correlates With a Transient Clinical Effect In Patients With Chronic Lymphocytic Leukemia

The Gold Compound Auranofin Induces Oxidative Stress and Apoptosis in Primary CLL Cells Independent of Classic Prognostic Markers and the Protective Effect of the Tissue Microenvironment

Pre-Clinical Efficacy of Combined Therapy with LSD1 Antagonist SP-2509 and Pan-Histone Deacetylase Inhibitor Against AML Blast Progenitor Cells

Pre-Clinical Efficacy of Combined Therapy with Novel β-Catenin Antagonist BC2059 and Histone Deacetylase Inhibitor Against Cultured and Primary AML Blast Progenitor Cells

Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists

Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate

Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor–resistant acute myeloid leukemia cells

HDAC6 inhibition enhances 17-AAG–mediated abrogation of hsp90 chaperone function in human leukemia cells

Pan-Histone Deacetylase (HDAC) Inhibitor LBH589 Depletes CXCR4 Levels and Signaling, Exerting Synergistic Anti-Leukemia Activity in Combination with CXCR4 Antagonists.

Connectivity Mapping of BCL6 Targeted Therapy Guides Rational Design of Potent and Specific Non-Chemotherapy Combinatorial Regimens in DLBCL.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only